Contact About Find a doctor Careers The Alfred Foundation For staff

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials

Clear filter

604 clinical trials found

Clinical trials

V940-001

A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (NCT05933577)

No longer recruiting

VANTAGE

VANTAGE Clinical Trial: (Evaluation of TAVI using the NAVITOR valve in a Global Investigation) (NCT04788888)

Currently recruiting

VBE00001

A Phase I/II, randomized, placebo-controlled, multi-arm, dose-finding study to evaluate the safety, efficacy and immunogenicity of an Acne mRNA vaccine candidate in adults with moderate to severe acne 18 to 45 years of age (NCT06316297)

The aim of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 administrations of the Acne mRNA vaccine candidate at up to 3 dose levels (45 µg, 120 µg and 225 µg total mRNA) in adults aged 18 to 45 years with moderate to severe acne. This is a phase I/II trial, in which about 260 people will take part in this study worldwide. 36/260 will be randomized in Sentinel cohort A, 200 participants in the main cohort A and 24 participants in Sentinel cohort B.

Currently recruiting

VECTORS

An Interventional Study to Evaluate Treating to a Target of Transmural Healing in Patients with Moderately to Severely Active Crohn’s Disease [VECTORS] (NCT06257706)

Currently recruiting

VELOCITY-HNSCC GS-US-699-7184

A Phase 2 Platform Study of Novel Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma VELOCITY-HNSCC Substudy-01: A Phase 2 Study of Novel Combination Therapies in Participants With Previously Untreated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status (NCT06727565)

Currently recruiting

Velora Discover - HMB-002-101_SCR

A Prospective, Screening Study of Bleeding and Treatment in Participants with Von Willebrand Disease

This is a non-interventional observational study in participants with confirmed Type 1 VWD according to diagnostic guidelines. The study includes screening, a baseline evaluation, and an approximately 4-month observation period which will include every other week telemedicine check-ins (to monitor bleed diary entries and bleeding event treatments.?

Currently recruiting

VENTURA-LT

An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) (NCT05518149)

Currently recruiting

VENTYX

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants with Moderately to Severely Active Crohn's Disease (NCT05688852)

Currently recruiting

VERTEX

A Phase 1/2, Randomized, Double-blind, Placebo controlled Single- and Multiple dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX 670 in Adult Subjects with Myotonic Dystrophy Type 1 (NCT06185764)

Currently recruiting

VERTEX

A Phase 1/2, Randomized, Double-blind, Placebo controlled Single- and Multiple-dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects with Myotonic Dystrophy Type 1 (NCT06185764)

Currently recruiting

Vertex OLE

An Open-label Extension Study Evaluating the Long-term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects with Myotonic Dystrophy Type I (NCT06926621)

Currently recruiting

VIALE-T

A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T) (NCT04161885)

Currently recruiting

VISOR

Virtual Reality Integrated Social Recovery therapy for Young People with Early Psychosis (ACTRN12624000234516)

This study aims to test the effectiveness of a new and improved version (version 2) of a virtual reality intervention designed to support the social and cognitive recovery of young people with early psychosis. The study will compare version 2 with the previous version 1, to determine if the new version is more effective in improving social functioning.

Currently recruiting

Vista Study

Navitor Post-Market Clinical Follow Up Study [VISTA Study] (NCT06008080)

Currently recruiting

VM-002-101

A first-in-human, phase 1, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary evidence of antitumor activity of IDOV-Immune in adult participants with advanced solid tumors (NCT06910657)

This is a Phase I clinical trial evaluating an investigational treatment called IDOVImmune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor. The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors. Participants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer. This study is being conducted at multiple sites in the United States and Australia.

Currently recruiting

VX20-121-104

A Phase 3, Open-Label Study Evaluating the Long-Term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (NCT05444257)

No longer recruiting

VX21-522-001

A Phase 1/2 Dose-escalation Study Evaluating the Safety, Tolerability, and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy (NCT05668741)

Currently recruiting

XENON 301-XTOLE2

A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures (NCT05614063)

Currently recruiting

XENON 303-X-ACKT

A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures (NCT05667142)